you are here: HomeNewsBiocon
biocon
Jump to
1508 Results Found
  • Biocon-Mylan gets USFDA nod to launch first biosimilar of cancer drug Neulasta Jun 05, 2018 09:50 AM IST

    Biocon-Mylan gets USFDA nod to launch first biosimilar of cancer drug Neulasta

    Neulasta had US sales of USD 4.2 billion for the 12 months ending March 31, 2018, according to IQVIA

  • Buy or sell: Top stock trading ideas by Dinesh Rohira, Prakash Gaba & Rajesh Agarwal for May 21 May 21, 2018 08:50 AM IST

    Buy or sell: Top stock trading ideas by Dinesh Rohira, Prakash Gaba & Rajesh Agarwal for May 21

    Prakash Gaba of prakashgaba.com is of the view that one can buy Biocon with target at Rs 665 and stop loss at Rs 635 and sell DCB Bank with target at Rs 175 and stop loss at Rs 184.

  • USFDA observations on Biocon's Bengaluru facility purely procedural May 18, 2018 05:07 PM IST

    USFDA observations on Biocon's Bengaluru facility purely procedural

    Analysts may not be serious enough to cause delay of the much anticipated approval of biosimilar Pegfilgrastim in US market.

  • Biocon sells 1.88% stake in Syngene for Rs 230 cr May 18, 2018 12:47 PM IST

    Biocon sells 1.88% stake in Syngene for Rs 230 cr

    In a separate filing, Syngene said Biocon has sold the shares for achieving minimum public shareholding requirement.

  • Set for FY19 biosimilar launches, Biocon says it will address observations by US, Europe regulators May 17, 2018 06:59 PM IST

    Set for FY19 biosimilar launches, Biocon says it will address observations by US, Europe regulators

    Biocon’s hopes of getting approvals for three major biosimiar products approved in US and Europe, now hinges on addressing the observations raised by US FDA and Europe drug regulator European Medicines Agency (EMA) on its Bengaluru facility.

  • Four cos added to MSCI India index May 15, 2018 01:25 PM IST

    Four cos added to MSCI India index

    InterGlobe soared 5 percent to Rs 1,248.55 and Biocon went up 2.49 percent to Rs 650.

  • Biocon gets 7 USFDA observations for Bengaluru drug facility May 02, 2018 10:31 PM IST

    Biocon gets 7 USFDA observations for Bengaluru drug facility

    The USFDA has completed pre-approval inspection of the sterile drug product manufacturing facility in Bengaluru this week and issued a Form 483 with 7 observations, the filing said.

  • Biocon likely to give 10% upside: Akash Jain Apr 30, 2018 02:37 PM IST

    Biocon likely to give 10% upside: Akash Jain

    "At current market price, there is little comfort on the valuation front. We expect moderate upside of 10 percent from current level as we believe the valuations are expensive," says Akash Jain, Vice-president, Equity Research at Ajcon Global Services.

  • Biocon net profit rises 2% in Q4 weighed by higher interest & depreciation costs related to Malaysian unit Apr 26, 2018 08:48 PM IST

    Biocon net profit rises 2% in Q4 weighed by higher interest & depreciation costs related to Malaysian unit

    Total revenue for the quarter under review grew 27 percent to Rs 1,237 crore in the January-March period.

  • Morgan Stanley overweight on Biocon, sees significant upside from its biosimilar pipeline Apr 13, 2018 09:48 AM IST

    Morgan Stanley overweight on Biocon, sees significant upside from its biosimilar pipeline

    The house is of the view that H2 seems to be strong for the company and Mylan with monetisation prospects of biosimilar pipeline improving. The firm expects significant upside from its biosimilar pipeline in 2019-2021.

  • Biocon partner Mylan enters pact with Fujifilm to commercialise Humira biosimilar in Europe Apr 11, 2018 09:51 PM IST

    Biocon partner Mylan enters pact with Fujifilm to commercialise Humira biosimilar in Europe

    Mylan said its partner Biocon will receive economic benefit through this collaboration.

  • Immediate resistance for Nifty at 10,440; top 5 stocks to buy which can return up to 15% Apr 10, 2018 11:59 AM IST

    Immediate resistance for Nifty at 10,440; top 5 stocks to buy which can return up to 15%

    "Nifty has immediate resistance zone at 10,420-10,440 levels. Crossing this zone on sustainable basis, next zone for index is seen at 10,560-10,630 where 50 percent of rise and February congestion highs are seen," Ashish Chaturmohta, Head Technical and Derivatives at Sanctum Wealth Management said in an exclusive interview with Moneycontrol's Kshitij Anand.

  • Pullback rally on Nifty could extend towards 10,500 levels; 3 stocks to track Apr 04, 2018 09:20 AM IST

    Pullback rally on Nifty could extend towards 10,500 levels; 3 stocks to track

    The ongoing correction could possibly continue with an intermediate support around 10,100-10,150 levels. The advance and decline ratio is in the favor of bulls which add to our conviction.

  • We expect roll out of insulin glargine in Europe to start in second half of 2018, says Biocon Mar 29, 2018 12:06 PM IST

    We expect roll out of insulin glargine in Europe to start in second half of 2018, says Biocon

    Biocon and its partner Mylan on Thursday said they have received approval for insulin glargine in Europe and Australia

  • Biocon, Mylan get European Commission nod to market biosimilar insulin glargine Mar 28, 2018 08:25 PM IST

    Biocon, Mylan get European Commission nod to market biosimilar insulin glargine

    Biotechnology major Biocon and Mylan today said their co-developed biosimilar insulin glargine has received marketing authorisation approval from the European Commission (EC).

  • Plan to enter EU market with Insulin Glargine in second half of the year: Biocon Mar 28, 2018 03:21 PM IST

    Plan to enter EU market with Insulin Glargine in second half of the year: Biocon

    We are now ready to enter the European market with our Insulin Glargine as a biosimilar, in the second half of this year, said Kiran Mazumdar Shaw, CMD, Biocon.

  • Biocon gets Europe and Australia approval to sell insulin glargine Mar 28, 2018 09:29 AM IST

    Biocon gets Europe and Australia approval to sell insulin glargine

    Insulin glargine is a biosimilar version of Sanofi's top selling Lantus. Insulin glargine is a long acting insulin that renoves patients from administering multiple injections in a day.

  • Market Update: PSU bank, metal stocks push Sensex, Nifty higher; SBI, IOC jump 3-4%, ICICI Bank most active Mar 27, 2018 10:04 AM IST

    Market Update: PSU bank, metal stocks push Sensex, Nifty higher; SBI, IOC jump 3-4%, ICICI Bank most active

    The market breadth was in favour of the advances with 1331 stocks advancing while 392 declined and 301 remained unchanged. On the other hand, in the BSE, 1868 stocks advanced and 704 declined and 138 remained unchanged.

  • Syngene inks pact with GSK for new drug discovery Mar 26, 2018 03:30 PM IST

    Syngene inks pact with GSK for new drug discovery

    The multi-year R&D agreement between the two companies will focus on accelerating the discovery of new drug candidates using Syngene's discovery services platforms, Syngene International said in a regulatory filing.

  • Syngene's multi-year agreement with GSK to focus on research: Jonathan Hunt Mar 26, 2018 01:56 PM IST

    Syngene's multi-year agreement with GSK to focus on research: Jonathan Hunt

    The agreement with GSK is more to support their research focus and not a specific drug pipeline, said Jonathan Hunt, CEO, Syngene International

  • USFDA finds discrepancies in production, quality and lab control systems at Biocon's Malaysian insulin site Mar 13, 2018 12:43 PM IST

    USFDA finds discrepancies in production, quality and lab control systems at Biocon's Malaysian insulin site

    The USFDA inspected Biocon's insulins facility in Johar, Malaysia last month

  • Top buy & sell ideas by Ashwani Gujral, Mitessh Thakkar & Prakash Gaba for March 12 Mar 12, 2018 08:30 AM IST

    Top buy & sell ideas by Ashwani Gujral, Mitessh Thakkar & Prakash Gaba for March 12

    Ashwani Gujral of ashwanigujral.com recommends buying Tech Mahindra with a stop loss of Rs 614 and target of Rs 635 and has a buy also on Tata Consultancy Services with a stop loss of Rs 3000, target of Rs 3150.

  • Top buy & sell ideas by Ashwani Gujral, Mitessh Thakkar & Prakash Gaba for March 9 Mar 09, 2018 08:28 AM IST

    Top buy & sell ideas by Ashwani Gujral, Mitessh Thakkar & Prakash Gaba for March 9

    Ashwani Gujral of ashwanigujral.com recommends buying Titan Company with a stop loss of Rs 810, target of Rs 840, Reliance Industries with a stop loss of Rs 900, target of Rs 925 and a buy also on Jubilant Foodworks with a stop loss of Rs 1990, target of Rs 2050.

  • Buy Biocon, LIC Housing, Voltas; sell TVS Motor, Century Textiles, Interglobe Aviation: Ashwani Gujral Mar 06, 2018 02:24 PM IST

    Buy Biocon, LIC Housing, Voltas; sell TVS Motor, Century Textiles, Interglobe Aviation: Ashwani Gujral

    Ashwani Gujral of ashwanigujral.com is of the view that one can buy Biocon, LIC Housing and Voltas and can sell TVS Motor, Century Textiles and Interglobe Aviation.

  • I feel NHPS has not been thought through fully: Kiran Mazumdar-Shaw Feb 26, 2018 12:27 PM IST

    I feel NHPS has not been thought through fully: Kiran Mazumdar-Shaw

    Mazumdar-Shaw welcomed the healthcare plan but said it is not viable unless it is integrated with primary healthcare.

Sections